Table 2.
Baseline risk factor analysis for fibrosis.
| Baseline features | SF (n = 16) | No SF (n = 48) | p |
|---|---|---|---|
| Age | 74.38 ± 10.72 | 71.73 ± 9.26 | 0.345 |
| Gender, male, n (%) | 6 (37.50) | 28 (58.33) | 0.148 |
| History of HTN or DM or HPL, n (%) | 7 (43.75) | 31 (64.58) | 0.142 |
| Ever smokers, n (%) | 12 (75.00) | 35 (72.92) | 1.000 |
| Drug | 0.655 | ||
| Conbercept | 7 (43.75) | 25 (52.08) | |
| Aflibercept | 2 (12.50) | 8 (16.67) | |
| Ranibizumab | 7 (43.75) | 15 (31.25) | |
| Number of injections | 4.00 (3.00, 4.25) | 4.00 (3.00, 5.25) | 0.407 |
| BCVA (LogMAR) | 1.00 (0.98, 1.30) | 0.65 (0.30, 0.94) | <0.001* |
| CMT (μm) | 452.25 (331.87, 552.92) | 286.25 (192.25, 371.00) | 0.009* |
| SRF, n (%) | 8 (50.00) | 23 (47.92) | 0.885 |
| IRF, n (%) | 9 (56.25) | 8 (16.67) | 0.005* |
| SHRM, n (%) | 14 (87.50) | 25 (52.08) | 0.012* |
| HF, n (%) | 13 (81.25) | 24 (50.00) | 0.028* |
| Lesion type | |||
| Type1, n (%) | 3 (18.75) | 18 (37.50) | 0.167 |
| Type2, n (%) | 9 (56.25) | 6 (12.50) | 0.001* |
| Type3, n (%) | 0 (0.00) | 8 (16.67) | 0.190 |
| PCV, n (%) | 4 (25.00) | 16 (33.33) | 0.533 |
| PED, n (%) | 4 (25.00) | 24 (50.00) | 0.081 |
| Ez loss, n (%) | 13 (81.25) | 27 (56.25) | 0.074 |
| Retinal hemorrhage, n (%) | 5 (31.25) | 8 (16.67) | 0.370 |
*Statistically significant (p < 0.05).